The Significance Of Glioma MGMT Protein Expression And MGMT Gene Promoter Methylation In Clinical Treatment

Objective:to MGMT gene promoter methylation zone with drug resistance has the close relation, this study was to explore the different level preliminary MGMT the protein expression and a gene promoter methylation relationship, for clinical overcome cancer chemotherapy drug resistance, personalized treatment glioma lay the foundation.Methods:using immunohistochemistry and methylation specific PCR (MSP) method, respectively of42patients with glioma organization and normal brain tissue,10cases of testing, testing its MGMT protein expression and gene promoter methylation situation, and the statistical analysis of the differences.Results:in this study,10cases of normal brain tissue monitoring a MGMT protein expression.42patients with glioma tissue samples from methylation in the positive rate was47.6%(20/42). According to the WHO pathology classification of Ⅱ, Ⅲ, Ⅳ level organization MGMT expression of gliomas were52.4%,53.3%and66.7%respectively. Among the three statistical method by comparing, no statistical significance.42cases the midbrain glioma tissue samples from MGMT in protein expression of positive there are23cases, and at the same time methylation is positive in7cases, positive rate was30.4%, and19cases MGMT protein expression of negative specimen,13cases methylation is positive, positive rate was68.4%, through analysis of related coefficient Spearman, was negatively correlated.Conclusion:MGMT gene promoter methylation may be involved in the tumors, and lead to cancer chemotherapy drug resistance, so the test organization MGMT methylation situation early diagnosis of tumors can be used as an index, also used as a clinical personalized chemotherapy a basis.